Literature DB >> 24176120

Prostate histotripsy: evaluation of prostatic urethral treatment parameters in a canine model.

George R Schade1, Nicholas R Styn, Kimberly A Ives, Timothy L Hall, William W Roberts.   

Abstract

OBJECTIVE: To assess the impact of histotripsy treatment parameters (pulse number and pulse-repetition frequency [PRF]) on the efficiency of histotripsy induced homogenisation of the prostatic urethra.
MATERIALS AND METHODS: In all, 34 transabdominal prostate histotripsy treatments were applied along a perpendicular plane traversing the prostatic urethra of 21 dogs. Prostate histotripsy was applied with (i) escalating pulse number with fixed PRF or (ii) at fixed pulse number with varying PRFs. The development of urethral homognisation ≤14 days of histotripsy was evaluated endoscopically and confirmed histologically.
RESULTS: Within 14 days of histotripsy 50%, 83%, 83%, and 100% of dogs receiving 12 500, 25 000, 50 000, and 100 000 pulses/mm of treatment path (delivered at 500 Hz PRF), respectively developed prostatic urethral disintegration. Delivery of 100 000 pulses/mm was required to achieve urethral disintegration in all dogs within 24 h of histotripsy treatment. Increasing histotripsy PRF from 50 to 500 to 2000 Hz while applying a constant dose of 25 000 pulses/mm treatment was associated with increased rate of urethral disintegration (50% vs 75% vs 100% at 14 days, respectively).
CONCLUSIONS: Increasing the number of histotripsy pulses and/or increasing the PRF of histotripsy treatment applied to the urethra may improve the rate and efficiency of prostatic urethral disintegration in the canine model. This understanding will aid in the development of treatment strategies for prostate histotripsy for benign prostatic hyperplasia in human trials.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  benign prostatic hyperplasia (BPH); focused ultrasound; prostate

Mesh:

Year:  2013        PMID: 24176120      PMCID: PMC3944657          DOI: 10.1111/bju.12333

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  26 in total

1.  An efficient treatment strategy for histotripsy by removing cavitation memory.

Authors:  Tzu-Yin Wang; Zhen Xu; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  Ultrasound Med Biol       Date:  2012-03-06       Impact factor: 2.998

2.  Controlled ultrasound tissue erosion.

Authors:  Zhen Xu; Achiau Ludomirsky; Lucy Y Eun; Timothy L Hall; Binh C Tran; J Brian Fowlkes; Charles A Cain
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2004-06       Impact factor: 2.725

3.  Controlled ultrasound tissue erosion: the role of dynamic interaction between insonation and microbubble activity.

Authors:  Zhen Xu; J Brian Fowlkes; Edward D Rothman; Albert M Levin; Charles A Cain
Journal:  J Acoust Soc Am       Date:  2005-01       Impact factor: 1.840

4.  Pulsed cavitational ultrasound therapy for controlled tissue homogenization.

Authors:  Jessica E Parsons; Charles A Cain; Gerald D Abrams; J Brian Fowlkes
Journal:  Ultrasound Med Biol       Date:  2006-01       Impact factor: 2.998

5.  A real-time measure of cavitation induced tissue disruption by ultrasound imaging backscatter reduction.

Authors:  Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2007-03       Impact factor: 2.725

6.  Effects of acoustic parameters on bubble cloud dynamics in ultrasound tissue erosion (histotripsy).

Authors:  Zhen Xu; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  J Acoust Soc Am       Date:  2007-07       Impact factor: 1.840

7.  Optical and acoustic monitoring of bubble cloud dynamics at a tissue-fluid interface in ultrasound tissue erosion.

Authors:  Zhen Xu; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  J Acoust Soc Am       Date:  2007-04       Impact factor: 1.840

8.  Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia.

Authors:  S Madersbacher; G Schatzl; B Djavan; T Stulnig; M Marberger
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

9.  Tissue thermometry during ultrasound exposure.

Authors:  K Hynynen; A Darkazanli; C A Damianou; E Unger; J F Schenck
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

10.  Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound.

Authors:  S Madersbacher; C Kratzik; M Susani; M Marberger
Journal:  J Urol       Date:  1994-12       Impact factor: 7.450

View more
  5 in total

1.  Histotripsy of the Prostate in a Canine Model: Characterization of Post-Therapy Inflammation and Fibrosis.

Authors:  Sarah E Darnell; Timothy L Hall; Scott A Tomlins; Xu Cheng; Kimberly A Ives; William W Roberts
Journal:  J Endourol       Date:  2015-02-18       Impact factor: 2.942

Review 2.  Targeted microbubbles: a novel application for the treatment of kidney stones.

Authors:  Krishna Ramaswamy; Vanessa Marx; Daniel Laser; Thomas Kenny; Thomas Chi; Michael Bailey; Mathew D Sorensen; Robert H Grubbs; Marshall L Stoller
Journal:  BJU Int       Date:  2015-03-17       Impact factor: 5.588

3.  Development of Tough Hydrogel Phantoms to Mimic Fibrous Tissue for Focused Ultrasound Therapies.

Authors:  Yashwanth Nanda Kumar; Zorawar Singh; Yak-Nam Wang; George R Schade; Wayne Kreider; Matthew Bruce; Eli Vlaisavljevich; Tatiana D Khokhlova; Adam D Maxwell
Journal:  Ultrasound Med Biol       Date:  2022-06-10       Impact factor: 3.694

4.  Endocavity Histotripsy for Efficient Tissue Ablation-Transducer Design and Characterization.

Authors:  Greyson E Stocker; Man Zhang; Zhen Xu; Timothy L Hall
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2021-08-27       Impact factor: 3.267

5.  Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound.

Authors:  Zhen Xu; Timothy L Hall; Eli Vlaisavljevich; Fred T Lee
Journal:  Int J Hyperthermia       Date:  2021       Impact factor: 3.753

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.